Genelux (United States)

Genelux (United States)

Genelux Corporation is a late clinical-stage public company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Genelux (United States), United States, covering academic research published from 2003 to 2019. Read More.


Open Access Percentage

73%


Total
Publications

132


Total Open
Publications

96


Total
Citations

3.9K


Open Access
Percentage

73%


Total
Publications

132


Total Open
Publications

96


Total
Citations

3.9K

Wikipedia

Website

download

Breakdown

9% 52% 12% 27%

Publisher Open

9%

Both

52%

Other Platform Open

12%

Closed

27%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
20032004200520062007200820092010201120122013201420152016201720182019

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0246810121416182022Total Publications
20032004200520062007200820092010201120122013201420152016201720182019

Open

Closed

Publisher Open

55%OA Journal

OA Journal 55%

44

Hybrid 15%

12

No Guarantees 30%

24

Other Platform Open

Domain 96%

81

Institution 49%

41

Public 20%

17

Other Internet 5%

4

Preprint 0%

0

Other Platform Locations

Name

Platform Type

Publications

Europe PMC
Domain
82
PubMed Central
Domain
81
Würzburg University - Online Publication Service of Würzburg University
Institution
35
Semantic Scholar
Public
16
Cold Spring Harbor Laboratory - Cold Spring Harbor Laboratory Institutional Repository
Institution
4
unige.it OAI-PMH Repository
Institution
2
Figshare
Public
2
DOI
Other Internet
2
whiterose.ac.uk OAI-PMH Repository
Institution
1
University of Twente - University of Twente Research Information
Institution
1
1 / 2

Data updated 14 March 2024

Share

Share

Share